GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of Denmark: dual agonist, and what it actually costs here — 31 comments in the full submission. View in context.
610
c/survodutide·submitted 9 months ago by u/whois_wanda

Denmark: dual agonist, and what it actually costs here

Trial Databranch of 9 comments

Been lurking in c/t2dglp1 for about 9 months and finally have something worth posting. Short version: week 26, 0.25mg, and hepatic fat is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 29 threads, and the answers split roughly down the middle. What I actually want to know…

Read the full submission and all 31 comments →

This branch

9 comments, started 9 months ago
u/chidi_demir96 points·9 months ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/tomas_lokken56 points·9 months ago

Australia here. Waited 9 months on a list, gave up, went private, and the total cost was roughly what I expected.

replysharereportpermalink
u/teodor_szabo44 points·9 months ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/crosspost_bot_no26 points·9 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/certified_referenceQC30 points·9 months ago

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

replysharereportpermalink
u/quant_not_qual24 points·9 months ago·edited

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/samir_falk14 points·9 months ago

I am going to push back on this slightly.

replysharereportpermalink
u/rania_marchand7 points·9 months ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/annika_fonseca22 points·9 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →